

Supporting Information

Base-Free Ni-Catalyzed Suzuki-Type Cross-Coupling Reactions of Epoxides with Boronic Acids

Table of Contents

1. General Information	S2
1.1 Materials	S2
1.2 Analytical Methods	S2
2. Preparation of Substrates.....	S3
2.1 Synthesis of epoxides	S3
2.2 Rferences	S3
3. General Experimental Procedures	S4
3.1 General procedure for Table 1	S4
3.2 General procedure for Table 2	S5
3.3 General procedure for Table 3.....	S5
3.3 General procedure for Table 4.....	S5
3.3 General procedure for scheme 2	S5
4. Substrate Scope and Spectral Data	S6
5. NMR Spectra	S23

1. General Information

1.1 Materials

The following chemicals were purchased and used as received: NiBr₂·diglyme (Aldrich, CAS: 312696-09-6), 4,4'-Di-tert-butyl-2,2'-bipyridine (dtbpy, CAS: 72914-19-3, Aldrich), Nickel(II) iodide (CAS: 13462-90-3, Alfa), NiCl₂(PPh₃)₂ (CAS: 14264-16-5, Adamas-beta), Cyclohexene oxide (CAS: 286-20-4, Adamas-beta), Isobutylene Oxide (CAS: 558-30-5, TCI), Cyclopentene oxide (CAS: 285-67-6, J&K), 2-hexyloxirane (CAS: 2984-50-1, Alfa), NaI (dry, anhydrous, Sinopharm Chemical Reagent Co., Ltd.), EtOH (Hengyue Chemical Technology Co., Ltd., 4 Å molecular sieves).


All the other reagents and solvents mentioned in this text were purchased from commercial sources and used without purification.

1.2 Analytical Methods


¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded on a Bruker 400 MHz spectrometer at 295 K in CDCl₃ unless otherwise noted. ¹⁹F NMR were reported as ¹⁹F exp. comp. pulse decoupling (F19CPD) unless otherwise noted. Data for ¹H-NMR are reported as follows: chemical shift (δ ppm), multiplicity, integration, and coupling constant (Hz). Data for ¹³C-NMR are reported in terms of chemical shift (δ ppm), multiplicity, and coupling constant (Hz). Gas chromatographic (GC) analysis was acquired on a Shimadzu GC-2014 Series GC System equipped with a flame-ionization detector. GC-MS analysis was performed on Thermo Scientific AS 3000 Series GC-MS System. HRMS ESI-mass data were acquired on Thermo LTQ Orbitrap XL instrument. Organic solutions were concentrated under reduced pressure on a Buchi rotary evaporator. Column chromatographic purification of products was accomplished using forced-flow chromatography on Silica Gel (200-300 mesh).

2. Preparation of Substrates

2.1 Synthesis of substrates



To a solution of potassium tertbutoxyde (20 mmol) in DMSO (20 mL) at room temperature was added trimethylsulfoxonium iodide (1.1 equiv.) and stirred for 30 min. A solution of acetophenone (20 mmol) in DMSO (15 mL) was added and stirred overnight. The reaction mixture was diluted with EtOAc and water and the layers were separated. The aqueous layer was back-extracted with EtOAc. The combined organic extracts were washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure to provide the product. ¹H NMR (400 MHz, CDCl₃) δ 7.46-7.35 (m, 4H), 7.33-7.28 (m, 1H), 3.01 (d, J = 5.3 Hz, 1H), 2.84 (d, J = 5.5 Hz, 1H), 1.76 (s, 3H).¹



To a solution of dimethylsulfoxonium methylide, which was prepared under Ar from NaH of 60% dispersion in mineral oil (11.0 mmol) and trimethylsulfonium iodide (11.0 mmol) in 5 mL of anhydrous DMSO, was added benzyl 4-oxopiperidine-1-carboxylate (10.0 mmol) in 5 mL of DMSO dropwise. The resulting mixture was stirred at 55 °C for 6 h. The cooled reaction mixture was poured into water and extracted with EtOAc. The combined organic layers were washed with H₂O, brine and then dried over Na₂SO₄. The mixture was purified by column chromatography to afford the desired products.^{1c}

2.2 Rferences


1. (a) C. Molinaro, A.-A. Guilbault and B. Kosjek, *Org. Lett.*, **2010**, 12, 3772-3775; (b) X.-L. Lu, Y.-T. Liu, Q.-X. Wang, M.-H. Shen and H.-D. Xu, *Org. Chem. Front.*, **2016**, 3, 725-729; (c) J. J. Cui, M. Tran-Dubé, H. Shen, M. Nambu, P.-P. Kung, M. Pairish, L. Jia, J. Meng, L. Funk, I. Botrous, M. McTigue, N. Grodsky, K. Ryan, E. Padrique, G. Alton, S. Timofeevski, S. Yamazaki, Q. Li, H. Zou, J. Christensen, B. Mroczkowski, S. Bender, R. S. Kania and M. P. Edwards, *J. Med. Chem.*, **2011**, 54, 6342-6363.

3. General Experimental Procedures

3.1 General procedure for Table 1

In air, Catalyst (10 mol%), Ligand (12 mol%), Phenylboronic (0.5 mmol) acid and NaI (50 mol%) were added to a schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). Solvent (0.8 mL), Base (1.5 equiv.) and cyclohexene oxide (0.25 mmol) were added in turn by syringe. The resulting reaction mixture was stirred vigorously at the mentioned temperature for the indicated amount of time. Benzophenone was added as internal standard. The product was yielded by GC.

Table S1. Optimization of the reaction conditions



Entry	Catalyst	Ligand	Base	Solvent	Yield% (<i>d.r.</i>)
1	NiBr ₂ ·diglyme	dtbpy	LiO ^t Bu	DMAc	trace
2	NiBr ₂ ·diglyme	dtbpy	LiO ^t Bu	DME	trace
3	NiBr ₂ ·diglyme	dtbpy	LiO ^t Bu	THF	trace
4	NiBr ₂ ·diglyme	dtbpy	K ₃ PO ₄	DMAc	2
5	NiBr ₂ ·diglyme	dtbpy	K ₂ CO ₃	DMAc	19(7.5:1)
6	NiBr ₂ ·diglyme	dtbpy	LiOMe	DMAc	6(8:1)
7	NiBr ₂ ·diglyme	dtbpy	NaOAc	DMAc	7(8:1)
8	NiBr ₂ ·diglyme	dtbpy	Et ₃ N	DMAc	trace
9	NiBr ₂ ·diglyme	dtbpy	K ₂ CO ₃	DME	13(7:1)
10	NiBr ₂ ·diglyme	dtbpy	K ₂ CO ₃	THF	16(7:1)
11	NiBr ₂ ·diglyme	dtbpy	-	DMAc	30(8:1)
12	NiBr ₂ ·diglyme	dtbpy	-	HO ^t Bu	47(9:1)
14	NiBr ₂ ·diglyme	dtbpy	-	ⁱ PrOH	65(8.5:1)
15	NiBr₂·diglyme	dtbpy	-	EtOH	89(9:1)
16	NiI ₂	dtbpy	-	EtOH	29(8:1)
17	NiCl ₂ (PPh ₃) ₂	dtbpy	-	EtOH	20(7:1)
18	NiBr ₂ ·diglyme	Phen	-	EtOH	25(8:1)
19 ^b	-	dtbpy	-	EtOH	0
20 ^c	NiBr ₂ ·diglyme	dtbpy	-	EtOH	trace
21 ^d	NiBr ₂ ·diglyme	dtbpy	-	EtOH	trace
22 ^e	NiBr ₂ ·diglyme	dtbpy	-	EtOH	trace
23 ^f	NiBr ₂ ·diglyme	dtbpy	-	EtOH	2
24	NiBr ₂ ·diglyme	dtbpy	-	MeOH	21(8:1)
25	NiBr ₂ ·diglyme	dtbpy	-	HFIP	12(8:1)
26	NiBr ₂ ·diglyme	dtbpy	-	H ₂ O	trace

Supporting Information

27 ^d	NiBr ₂ ·diglyme	dtbpy	LiOMe	EtOH	3
28 ^d	NiBr ₂ ·diglyme	dtbpy	LiO ^t Bu	EtOH	trace
28 ^d	NiBr ₂ ·diglyme	dtbpy	K ₂ CO ₃	EtOH	5

^a **Reaction conditions:** 1a (0.5 mmol), 2a (0.25 mmol), Base (1.5 equiv.) in 0.8 mL solvent at 70 °C for 20 h. ^bno catalyst. ^c **Ph-Bpin** as substrate. ^d **Ph-B(neop)** as substrate. ^e **Ph-BMIDA** as substrate. ^f **Ph-BF₃K** as substrate. The yield was determined by GC using Benzophenone as internal standard. The *d.r.* ratio was determined by GC.

3.2 General procedure for Table 2

In air, NiBr₂·diglyme (10 mol%), dtbpy (12 mol%), Boronic acid (0.5 mmol) and NaI (50 mol%) were added to a schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). To these solids, EtOH (0.8 mL) and epoxy (0.25 mmol) were added in turn by syringe. The resulting reaction mixture was stirred vigorously at 70 °C for 20 h. The mixture was purified by column chromatography to afford the desired products. The *d.r.* ratio was determined by ¹H & GC.

3.3 General procedure for Table 3

In air, NiBr₂·diglyme (10 mol%), dtbpy (12 mol%), (E)-styrylboronic acid (0.5 mmol) and NaI (50 mol%) were added to a schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). EtOH (0.8 mL) and epoxy (0.25 mmol) were added in turn by syringe. The resulting reaction mixture was stirred vigorously at 70 °C for 20 h. The mixture was purified by column chromatography to afford the desired products.


3.3 General procedure for Table 4

In air, NiBr₂·diglyme (10 mol%), dtbpy (12 mol%), Boronic acid (1.5 equiv.) and NaI (50 mol%) were added to a schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). EtOH (0.8 mL) and epoxy (0.3 mmol) were added in turn by syringe. The resulting reaction mixture was stirred vigorously at 70 °C for 20 h. The mixture was purified by column chromatography to afford the desired products.

3.3 General procedure for scheme 2


In air, NiBr₂·diglyme (10 mol%), dtbpy (12 mol%), (E)-styrylboronic acid (0.5 mmol) and NaI (50 mol%) were added to a schlenk tube equipped with a stir bar. The vessel was evacuated and filled with argon (three cycles). EtOH (0.8 mL) and 3,4-Epoxy-1-butene (0.25 mmol) were added in turn by syringe. The resulting reaction mixture was stirred vigorously at 70 °C for 20 h. The mixture was purified by column chromatography to afford the desired products.

4. Substrate Scope and Spectral Data




2-(3-(trifluoromethyl)phenyl)cyclohexan-1-ol

Prepared according to the general procedure, as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.53 – 7.47 (m, 2H), 7.46 – 7.40 (m, 2H), 3.68 (td, J = 10.1, 4.4 Hz, 1H), 2.57 – 2.45 (m, 1H), 2.17 – 2.06 (m, 1H), 1.92 – 1.83 (m, 2H), 1.81 – 1.73 (m, 1H), 1.57 – 1.28 (m, 5H). ^{19}F NMR (376 MHz, CDCl_3) δ -62.95. ^{13}C NMR (101 MHz, CDCl_3) δ 144.64, 131.38 (q, J = 1.1 Hz), 130.95 (q, J = 32.0 Hz), 129.05, 124.54 (q, J = 3.8 Hz), 124.21 (q, J = 272.3 Hz), 123.59 (q, J = 3.8 Hz), 74.18, 52.97, 34.87, 33.37, 25.88, 24.97. HRMS (APCI) calcd for $\text{C}_{13}\text{H}_{15}\text{F}_3\text{NaO}$ ($\text{M}+\text{Na}^+$): 267.0967; found: 267.0961.




2-phenylcyclohexan-1-ol

Prepared according to the general procedure, as a sticky solid. ^1H NMR (400 MHz, CDCl_3) δ 7.36 – 7.28 (m, 2H), 7.27 – 7.19 (m, 3H), 3.64 (td, J = 10.1, 4.3 Hz, 1H), 2.51 – 2.25 (m, 1H), 2.15 – 1.99 (m, 1H), 1.89 – 1.79 (m, 2H), 1.77 – 1.68 (m, 1H), 1.64 (br s, 1H), 1.57 – 1.25 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.35, 128.75, 127.94, 126.81, 74.40, 53.23, 34.47, 33.35, 26.08, 25.09. HRMS (APCI) calcd for $\text{C}_{12}\text{H}_{16}\text{NaO}$ ($\text{M}+\text{Na}^+$): 199.1093; found: 199.1098.




1-(4-(2-hydroxy-2-methylpropyl)phenyl)ethan-1-one


Prepared according to the general procedure, as a liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.89 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.3 Hz, 2H), 2.83 (s, 2H), 2.58 (s, 3H), 1.24 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 198.01, 143.85, 135.42, 130.69, 128.15, 70.83, 49.68, 29.32, 26.56. HRMS (APCI) calcd for $\text{C}_{12}\text{H}_{16}\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 215.1043; found: 215.1045.

**2-([1,1'-biphenyl]-4-yl)cyclohexan-1-ol**

Prepared according to the general procedure, as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.62 – 7.52 (m, 4H), 7.48 – 7.39 (m, 2H), 7.38 – 7.31 (m, 3H), 3.71 (td, $J = 10.1, 4.3$ Hz, 1H), 2.49 (ddd, $J = 13.2, 10.0, 3.5$ Hz, 1H), 2.15 (dd, $J = 6.0, 2.7$ Hz, 1H), 1.96 – 1.83 (m, 2H), 1.79 (dd, $J = 10.9, 4.6$ Hz, 1H), 1.62 – 1.56 (m, 1H), 1.56 – 1.46 (m, 1H), 1.46 – 1.30 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 142.39, 140.91, 139.80, 128.76, 128.31, 127.52, 127.17, 127.04, 74.46, 52.89, 34.56, 33.36, 26.07, 25.09. HRMS (APCI) calcd for $\text{C}_{18}\text{H}_{20}\text{NaO}$ ($\text{M}+\text{Na}^+$): 275.1406; found: 275.1409.


**2-(naphthalen-2-yl)cyclohexan-1-ol**

Prepared according to the general procedure, as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.86 – 7.75 (m, 3H), 7.70 (s, 1H), 7.51 – 7.35 (m, 3H), 3.75 (td, $J = 10.1, 4.3$ Hz, 1H), 2.59 (ddd, $J = 13.2, 10.0, 3.6$ Hz, 1H), 2.24 – 2.01 (m, 1H), 1.96 – 1.84 (m, 2H), 1.78 (dd, $J = 10.9, 4.1$ Hz, 1H), 1.69 – 1.55 (m, 2H), 1.53 – 1.30 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 140.75, 133.64, 132.64, 128.51, 127.67, 127.64, 126.73, 126.15, 125.97, 125.57, 74.29, 53.38, 34.51, 33.35, 26.11, 25.12. HRMS (APCI) calcd for $\text{C}_{16}\text{H}_{18}\text{NaO}$ ($\text{M}+\text{Na}^+$): 249.1250; found: 249.1253.

**2-([1,1'-biphenyl]-4-yl)cyclopentan-1-ol**


Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.62 – 7.48 (m, 4H), 7.45 – 7.35 (m, 2H), 7.34 – 7.27 (m, 3H), 4.16 (q, $J = 7.2$ Hz, 1H), 2.90 (dd, $J = 17.1, 8.0$ Hz, 1H), 2.26 – 2.05 (m, 2H), 1.93 – 1.62 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 142.51, 141.02, 139.42, 128.79, 127.88, 127.32, 127.15, 127.04, 80.45, 54.12, 34.07, 31.92, 21.82. HRMS (APCI) calcd for $\text{C}_{17}\text{H}_{18}\text{NaO}$ ($\text{M}+\text{Na}^+$): 261.1250;

found: 261.1256.




2-(4-(trifluoromethyl)phenyl)cyclohexan-1-ol

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.57 (d, $J = 8.1$ Hz, 2H), 7.34 (d, $J = 8.0$ Hz, 2H), 3.67 – 3.54 (m, 1H), 2.55 – 2.41 (m, 1H), 2.13 – 1.98 (m, 1H), 1.78 (ddd, $J = 39.7, 16.6, 4.1$ Hz, 4H), 1.57 – 1.23 (m, 4H). ^{19}F NMR (376 MHz, CDCl_3) δ -62.35. ^{13}C NMR (101 MHz, CDCl_3) δ 147.98 (q, $J = 1.1$ Hz), 128.90 (q, $J = 32.3$ Hz), 128.23, 125.50 (q, $J = 3.7$ Hz), 124.29 (q, $J = 271.8$ Hz), 74.07, 52.94, 34.91, 33.32, 25.83, 24.95. HRMS (APCI) calcd for $\text{C}_{13}\text{H}_{15}\text{F}_3\text{NaO}$ ($\text{M}+\text{Na}^+$): 267.0967; found: 267.0972.




4-(2-hydroxy-2-methylpropyl)benzonitrile

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, $J = 8.2$ Hz, 2H), 7.35 (d, $J = 8.2$ Hz, 2H), 2.82 (s, 2H), 1.61 (br s, 1H), 1.24 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.76, 131.79, 131.25, 119.01, 110.27, 70.85, 49.67, 29.41. HRMS (APCI) calcd for $\text{C}_{11}\text{H}_{13}\text{NNaO}$ ($\text{M}+\text{Na}^+$): 198.0889; found: 198.0887.




2-methyl-1-(3-(trifluoromethoxy)phenyl)propan-2-ol

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.33 (t, $J = 7.8$ Hz, 1H), 7.21 – 7.04 (m, 3H), 2.78 (s, 2H), 1.46 (br s, 1H), 1.23 (s, 6H). ^{19}F NMR (376 MHz, CDCl_3) δ -57.77. ^{13}C NMR (101 MHz, CDCl_3) δ 149.08, 140.17, 129.35, 128.87, 122.99, 120.50 (q, $J = 256.9$ Hz), 118.95, 70.75, 49.35, 29.22. HRMS (APCI) calcd for $\text{C}_{11}\text{H}_{13}\text{F}_3\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 257.0760; found: 257.0765.




1-phenyloctan-2-ol

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.32 (t, $J = 7.2$ Hz, 2H), 7.25 – 7.20 (m, 3H), 3.81 (ddd, $J = 13.0, 7.9, 4.5$ Hz, 1H), 2.83 (dd, $J = 13.5, 4.2$ Hz, 1H), 2.64 (dd, $J = 13.5, 8.4$ Hz, 1H), 1.53 – 1.44 (m, 3H), 1.36 – 1.24 (m, 7H), 0.88 (t, $J = 6.8$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 138.66, 129.43, 128.55, 126.43, 72.71, 44.06, 36.85, 31.84, 29.33, 25.74, 22.63, 14.10. (APCI) calcd for $\text{C}_{14}\text{H}_{22}\text{NaO}$ ($\text{M}+\text{Na}^+$): 229.1563; found: 229.1567.




2-(4-fluorophenyl)cyclohexan-1-ol

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.25 – 7.18 (m, 2H), 7.11 – 6.96 (m, 2H), 3.61 (td, $J = 10.1, 4.3$ Hz, 1H), 2.52 – 2.30 (m, 1H), 2.10 (ddd, $J = 7.5, 4.6, 1.9$ Hz, 1H), 1.88 – 1.80 (m, 2H), 1.79 – 1.73 (m, 1H), 1.53 – 1.25 (m, 4H). ^{19}F NMR (376 MHz, CDCl_3) δ -116.34. ^{13}C NMR (101 MHz, CDCl_3) δ 161.73 (d, $J = 244.6$ Hz), 139.02 (d, $J = 3.1$ Hz), 129.23 (d, $J = 7.8$ Hz), 115.50 (d, $J = 21.0$ Hz), 74.50, 52.42, 34.61, 33.50, 26.01, 25.03. HRMS (APCI) calcd for $\text{C}_{12}\text{H}_{15}\text{FNaO}$ ($\text{M}+\text{Na}^+$): 217.0999; found: 217.0991.




1-(3-(2-hydroxy-2-methylpropyl)phenyl)ethan-1-one

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.83 – 7.57 (m, 2H), 7.35 (m, 2H), 2.76 (s, 2H), 2.53 (s, 3H), 1.68 (br s, 1H), 1.16 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 198.44, 138.53, 137.02, 135.27, 130.17, 128.33, 126.59, 70.77, 49.46, 29.26, 26.69. HRMS (APCI) calcd for $\text{C}_{12}\text{H}_{16}\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 215.1043; found: 215.1046.




2,2-diphenylethan-1-ol

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.47 – 6.93 (m, 10H), 4.29 – 3.88 (m, 3H), 1.71 (br s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.43, 128.77, 128.37, 126.87, 66.17, 53.68. HRMS (APCI) calcd for $\text{C}_{14}\text{H}_{14}\text{NaO}$ ($\text{M}+\text{Na}^+$): 221.0937; found: 221.0933.




2-([1,1'-biphenyl]-4-yl)-2-phenylethan-1-ol

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.60 – 7.48 (m, 4H), 7.47 – 7.37 (m, 2H), 7.36 – 7.27 (m, 7H), 7.27 – 7.23 (m, 1H), 4.85 – 3.43 (m, 3H), 1.59 (br s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.38, 140.80, 140.53, 139.79, 128.84, 128.83, 128.78, 128.39, 127.50, 127.31, 127.09, 126.96, 66.18, 53.38. HRMS (APCI) calcd for $\text{C}_{20}\text{H}_{18}\text{NaO}$ ($\text{M}+\text{Na}^+$): 297.1250; found: 297.1257.



tert-butyl 4-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxypiperidine-1-carboxylate


Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.60 – 7.47 (m, 4H), 7.46 – 7.39 (m, 2H), 7.36 – 7.30 (m, 1H), 7.27 – 7.22 (m, 2H), 3.86 (d, $J = 13.1$ Hz, 2H), 3.33 – 2.88 (m, 2H), 2.78 (s, 2H), 1.69 – 1.50 (m, 4H), 1.46 (s, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 154.89, 140.75, 139.70, 135.23, 131.04, 128.84, 127.31, 127.08, 127.02, 79.46, 69.58, 48.93, 39.47, 36.67, 28.52. HRMS (APCI) calcd for $\text{C}_{23}\text{H}_{29}\text{NNaO}_3$ ($\text{M}+\text{Na}^+$): 390.2040; found: 390.2049.



1-(3-(2-hydroxycyclohexyl)phenyl)ethan-1-one


Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.87 (s, 1H), 7.83 (dt, $J = 7.3, 1.5$ Hz, 1H), 7.49 – 7.37 (m, 2H), 3.73 (td, $J = 10.1, 4.3$ Hz, 1H), 2.62 (d, $J = 4.1$ Hz, 3H), 2.57 – 2.48 (m, 1H), 2.19 – 2.05 (m, 1H), 1.95 – 1.84 (m, 2H), 1.78 (dd, $J = 11.1, 4.6$ Hz, 1H), 1.57 – 1.22 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ

198.23, 144.25, 137.55, 132.81, 128.92, 127.49, 126.97, 74.25, 53.07, 34.87, 33.44, 26.70, 25.95, 25.02. HRMS (APCI) calcd for C₁₄H₁₈NaO₂ (M+Na⁺): 241.1199; found: 241.1193.




(E)-2-methyl-5-phenylpent-4-en-2-ol

Prepared according to the general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.35 (m, 2H), 7.34 – 7.27 (m, 2H), 7.23 – 7.19 (m, 1H), 6.46 (d, *J* = 15.8 Hz, 1H), 6.35 – 6.24 (m, 1H), 2.39 (d, *J* = 7.5 Hz, 2H), 1.27 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 137.35, 133.70, 128.56, 127.28, 126.16, 125.79, 70.92, 47.36, 29.27. HRMS (APCI) calcd for C₁₂H₁₆NaO (M+Na⁺): 199.1093; found: 199.1096.



trans-2-((1E,3E)-4-phenylbuta-1,3-dien-1-yl)cyclohexan-1-ol


Prepared according to the general procedure, as a pale-yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.34 (m, 2H), 7.31 (t, *J* = 7.5 Hz, 2H), 7.25 – 7.17 (m, 1H), 6.53 (d, *J* = 15.9 Hz, 1H), 6.07 (dd, *J* = 15.9, 8.9 Hz, 1H), 3.34 (td, *J* = 9.9, 4.4 Hz, 1H), 2.13 – 2.00 (m, 2H), 1.87 – 1.77 (m, 3H), 1.73 – 1.65 (m, 1H), 1.35 – 1.24 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 137.07, 132.16, 131.98, 128.56, 127.38, 126.18, 73.25, 50.59, 33.89, 31.44, 25.22, 24.82. HRMS (APCI) calcd for C₁₄H₁₈NaO (M+Na⁺): 225.1250; found: 225.1257.



(E)-3-methyl-5-phenylpent-4-en-2-ol


Prepared according to the general procedure, as a pale-yellow liquid. The *d.r.* ratio was determined to be 1.6:1 by ¹H NMR. ¹H NMR of a mixture of two diastereomers (400 MHz, CDCl₃) δ 7.40 – 7.35 (m, 2H), 7.33 – 7.28 (m, 2H), 7.24 – 7.18 (m, 1H), 6.47 (dd, *J* = 16.0, 12.1 Hz, 1H), 6.15 (ddd, *J* = 17.5, 16.0, 8.3 Hz, 1H), 3.82 – 3.51 (m, 1H), 2.53 – 2.19 (m, 1H), 1.62 (s, 1H), 1.26 – 1.16 (m, 3H), 1.14 – 1.05 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 137.53, 137.29, 132.23, 131.80, 130.91, 128.70, 128.68, 127.48, 127.35, 126.30, 126.26, 71.49, 71.40, 45.62, 44.55, 20.48, 20.37, 16.73, 15.65. HRMS (APCI) calcd for C₁₂H₁₆NaO

(M+Na⁺): 199.1093; found: 199.1087.




(E)-5-phenylpent-4-en-2-ol

Prepared according to the general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 7.3 Hz, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.21 (dd, *J* = 13.2, 6.0 Hz, 1H), 6.48 (d, *J* = 15.9 Hz, 1H), 6.29 – 6.16 (m, 1H), 3.93 (dd, *J* = 12.2, 6.2 Hz, 1H), 2.46 – 2.22 (m, 2H), 1.25 (d, *J* = 6.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 137.27, 133.18, 128.56, 127.30, 126.29, 126.13, 67.42, 42.93, 22.91. HRMS (APCI) calcd for C₁₁H₁₄NaO (M+Na⁺): 185.0937; found 185.0941.




(E)-1-phenyldodeca-1,11-dien-4-ol

Prepared according to the general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, *J* = 7.5 Hz, 2H), 7.30 (t, *J* = 7.5 Hz, 2H), 7.22 (t, *J* = 7.2 Hz, 1H), 6.48 (d, *J* = 15.8 Hz, 1H), 6.28 – 6.10 (m, 1H), 5.87 – 5.70 (m, 1H), 5.04 – 4.87 (m, 2H), 2.49 – 2.39 (m, 1H), 2.34 – 2.25 (m, 1H), 2.04 (dd, *J* = 13.6, 6.4 Hz, 3H), 1.55 – 1.46 (m, 3H), 1.43 – 1.28 (m, 8H). ¹³C NMR (101 MHz, CDCl₃) δ 139.16, 137.25, 133.13, 128.55, 127.27, 126.37, 126.10, 114.19, 71.16, 41.16, 36.89, 33.78, 29.49, 29.08, 28.85, 25.66. HRMS (APCI) calcd for C₁₈H₂₆NaO (M+Na⁺): 281.1876; found: 281.1872.




(E)-4-phenyl-2-vinylbut-3-en-1-ol


Prepared according to the general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.34 (m, 2H), 7.35 – 7.27 (m, 2H), 7.27 – 7.18 (m, 1H), 6.50 (d, *J* = 16.0 Hz, 1H), 6.13 (dd, *J* = 16.0, 7.7 Hz, 1H), 5.88 – 5.63 (m, 1H), 5.34 – 5.13 (m, 2H), 3.65 (d, *J* = 6.8 Hz, 2H), 3.22 – 2.95 (m, 1H), 1.69 (br s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 137.38, 137.06, 132.25, 128.61, 128.58, 127.50, 126.24, 117.28, 65.24, 50.04. HRMS (APCI) calcd for C₁₂H₁₄NaO (M+Na⁺): 197.0937; found: 197.0933. The isolated product matched spectra previously reported in the literature. (*Ref. J. Am. Chem. Soc.*, 2016, **138**, 3655-3658).

**(2E,5E)-6-phenylhexa-2,5-dien-1-ol**

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.37 – 7.32 (m, 2H), 7.30 (t, J = 7.6 Hz, 2H), 7.20 (t, J = 7.2 Hz, 1H), 6.41 (d, J = 15.8 Hz, 1H), 6.28 – 6.15 (m, 1H), 5.84 – 5.64 (m, 2H), 4.14 (d, J = 5.1 Hz, 2H), 3.00 – 2.93 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 137.50, 130.96, 130.56, 130.28, 128.51, 128.03, 127.10, 126.04, 63.63, 35.49. HRMS (APCI) calcd for $\text{C}_{12}\text{H}_{14}\text{NaO}$ ($\text{M}+\text{Na}^+$): 197.0937; found: 197.0939. The isolated product matched spectra previously reported in the literature. (*Ref. Org. Lett.*, 2019, **21**, 3606-3609).


**2-(4-fluorophenyl)-2-phenylethan-1-ol**

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.42 – 7.28 (m, 3H), 7.28 – 7.16 (m, 4H), 7.06 – 6.91 (m, 2H), 4.25 – 3.99 (m, 3H), 1.70 (br s, 1H). ^{19}F NMR (376 MHz, CDCl_3) δ -116.14. ^{13}C NMR (101 MHz, CDCl_3) δ 161.71 (d, J = 245.2 Hz), 141.27, 137.24 (d, J = 3.2 Hz), 129.81 (d, J = 7.9 Hz), 128.83, 128.27, 126.98, 115.52 (d, J = 21.2 Hz), 66.12, 52.82. HRMS (APCI) calcd for $\text{C}_{14}\text{H}_{13}\text{FNaO}$ ($\text{M}+\text{Na}^+$): 239.0843; found: 239.0840.

**1-(3-(2-hydroxy-1-phenylethyl)phenyl)ethan-1-one**


Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.88 (t, J = 1.7 Hz, 1H), 7.80 (dt, J = 7.6, 1.5 Hz, 1H), 7.44 (ddd, J = 30.3, 10.7, 4.5 Hz, 2H), 7.34 – 7.28 (m, 2H), 7.28 – 7.21 (m, 3H), 4.30 – 4.22 (m, 1H), 4.21 – 4.15 (m, 2H), 2.56 (s, 3H), 1.91 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 198.40, 142.37, 140.95, 137.42, 133.28, 128.95, 128.87, 128.32, 127.96, 127.07, 127.03, 65.88, 53.50, 26.74. HRMS (APCI)

calcd for C₁₆H₁₆NaO₂ (M+Na⁺): 263.1043; found: 263.1046.




4-(2-hydroxy-1-phenylethyl)benzonitrile

Prepared according to the general procedure, as a pale-yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.62 – 7.54 (m, 2H), 7.42 – 7.30 (m, 4H), 7.29 – 7.17 (m, 3H), 4.33 – 4.05 (m, 3H), 1.75 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 147.38, 140.13, 132.42, 129.24, 129.02, 128.34, 127.38, 118.87, 110.54, 65.54, 53.52. HRMS (APCI) calcd for C₁₅H₁₃NNaO (M+Na⁺): 246.0889; found: 246.0885.



2-((1E,3E)-penta-1,3-dien-1-yl)cyclopentan-1-ol


Prepared according to the general procedure, as a pale-yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.59 (br s, 1H), 7.45 – 7.35 (m, 2H), 7.33 – 7.18 (m, 6H), 6.99 (d, *J* = 7.6 Hz, 1H), 4.43 – 3.71 (m, 3H), 2.08 (s, 3H, -CH₃), 2.04 (br s, 3H, -OH). ¹³C NMR (101 MHz, CDCl₃) δ 168.90, 142.55, 141.30, 138.27, 129.27, 128.71, 128.29, 126.85, 124.34, 119.89, 118.52, 65.89, 53.51, 24.46. HRMS (APCI) calcd for C₁₆H₁₇NNaO₂ (M+Na⁺): 278.1151; found: 278.1156.



(E)-2,4-diphenylbut-3-en-1-ol


Prepared according to the general procedure, as a pale-yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.32 (m, 4H), 7.32 – 7.25 (m, 4H), 7.24 – 7.19 (m, 2H), 6.52 (d, *J* = 16.0 Hz, 1H), 6.37 (dd, *J* = 15.9, 7.8 Hz, 1H), 3.97 – 3.80 (m, 2H), 3.69 (q, *J* = 7.3 Hz, 1H), 1.65 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 140.87, 136.99, 132.19, 129.75, 128.89, 128.61, 128.06, 127.57, 127.07, 126.32, 66.43, 51.87. HRMS (APCI) calcd for C₁₆H₁₆NaO (M+Na⁺):

247.1093; found: 247.1096.




2-(3-chlorophenyl)-2-phenylethan-1-ol

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.27 (m, 4H), 7.26 – 7.17 (m, 4H), 7.13 (d, J = 7.1 Hz, 1H), 4.24 – 3.92 (m, 3H), 1.96 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.69, 140.73, 134.53, 129.95, 128.90, 128.51, 128.33, 127.13, 127.03, 126.59, 65.86, 53.30. HRMS (APCI) calcd for $\text{C}_{14}\text{H}_{13}\text{ClNaO}$ ($\text{M}+\text{Na}^+$): 255.0547; found: 255.0542.




6-([1,1'-biphenyl]-4-yl)-2,2-dimethyl-1,3-dioxepan-5-ol

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.63 – 7.51 (m, 4H), 7.43 (ddd, J = 8.5, 4.4, 1.9 Hz, 2H), 7.39 – 7.30 (m, 3H), 4.52 (dt, J = 7.9, 6.0 Hz, 1H), 4.08 – 3.91 (m, 3H), 3.71 (t, J = 8.0 Hz, 1H), 3.16 – 2.95 (m, 1H), 1.71 (d, J = 24.7 Hz, 1H), 1.35 (d, J = 2.6 Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 140.76, 140.16, 137.33, 129.40, 128.80, 127.56, 127.29, 127.06, 109.03, 67.15, 64.42, 49.84, 26.51, 25.53. HRMS (APCI) calcd for $\text{C}_{19}\text{H}_{22}\text{NaO}_3$ ($\text{M}+\text{Na}^+$): 321.1461; found: 321.1463.




methyl 3-(2-hydroxycyclohexyl)benzoate

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 8.00 – 7.83 (m, 2H), 7.54 – 7.29 (m, 2H), 3.90 (s, 3H), 3.75 – 3.64 (m, 1H), 2.60 – 2.40 (m, 1H), 2.21 – 2.00 (m, 1H), 1.85 (ddd, J = 8.5, 7.1, 2.6 Hz, 2H), 1.81 – 1.74 (m, 1H), 1.60 – 1.18 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.16, 144.03, 132.83, 130.49, 128.80, 128.72, 128.02, 74.19, 52.96, 52.15, 34.79, 33.43, 25.96, 25.03. HRMS (APCI) calcd for $\text{C}_{14}\text{H}_{18}\text{NaO}_3$ ($\text{M}+\text{Na}^+$): 257.1148; found: 257.1143.




3-([1,1'-biphenyl]-4-yl)butan-2-ol

Prepared according to the general procedure, as a pale-yellow liquid. The *d.r.* ratio was determined to be 1.8:1 by ^1H NMR. ^1H NMR of a mixture of two diastereomers (400 MHz, CDCl_3) δ 7.53 – 7.43 (m, 4H), 7.35 (m, 2H), 7.27 – 7.17 (m, 3H), 4.02 – 3.63 (m, 1H), 2.79 – 2.47 (m, 1H), 1.30 – 1.20 (m, 3H), 1.19 – 0.99 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 143.39, 142.74, 140.96, 140.91, 139.69, 139.39, 128.82, 128.53, 128.34, 127.37, 127.30, 127.24, 127.17, 127.07, 127.05, 125.92, 72.44, 72.38, 47.64, 46.84, 21.13, 20.76, 17.95, 16.06. HRMS (APCI) calcd for $\text{C}_{16}\text{H}_{18}\text{NaO}$ ($\text{M}+\text{Na}^+$): 249.1250; found: 249.1255.



3-([1,1'-biphenyl]-4-ylmethyl)cyclopentan-1-ol


Prepared according to the general procedure, as a pale-yellow solid. The *d.r.* ratio was determined to be 1.2:1 by ^1H NMR. ^1H NMR of a mixture of two diastereomers (400 MHz, CDCl_3) δ 7.58 (d, $J = 7.6$ Hz, 2H), 7.50 (d, $J = 7.9$ Hz, 2H), 7.42 (t, $J = 7.5$ Hz, 2H), 7.31 (t, $J = 7.3$ Hz, 1H), 7.26 – 7.19 (m, 2H), 4.56 – 4.15 (m, 1H), 2.81 – 2.54 (m, 2H), 2.21 – 2.07 (m, 1H), 2.05 – 1.87 (m, 1H), 1.85 – 1.64 (m, 2H), 1.55 – 1.38 (m, 2H), 1.36 – 1.16 (m, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.13, 140.98, 140.88, 138.70, 129.24, 128.81, 128.76, 127.24, 127.04, 127.02, 127.00, 126.94, 73.71, 73.62, 42.53, 42.31, 42.20, 41.68, 40.34, 39.24, 35.44, 35.16, 30.39, 30.24. HRMS (APCI) calcd for $\text{C}_{18}\text{H}_{20}\text{NaO}$ ($\text{M}+\text{Na}^+$): 275.1406; found: 275.1403.



benzyl 4-benzyl-4-hydroxypiperidine-1-carboxylate


Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.40 – 7.22 (m, 8H), 7.17 (d, $J = 7.1$ Hz, 2H), 5.12 (s, 2H), 3.95 (br s, 2H), 3.16 (br s, 2H), 2.75 (s, 2H), 1.71 – 1.34 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 155.29, 136.89, 135.89, 130.55, 128.52, 128.50, 128.00, 127.89, 126.92, 69.36, 67.07, 49.31, 39.94, 36.63. HRMS

(APCI) calcd for C₂₀H₂₃NNaO₃ (M+Na⁺): 348.1570; found: 348.1573.




4-phenylisochromane

¹H NMR (400 MHz, CDCl₃) δ 7.33 – 7.26 (m, 2H), 7.26 – 7.15 (m, 4H), 7.11 (t, *J* = 7.4 Hz, 1H), 7.04 (d, *J* = 7.5 Hz, 1H), 6.94 (d, *J* = 7.7 Hz, 1H), 4.89 (q, *J* = 15.0 Hz, 2H), 4.16 (q, *J* = 5.0 Hz, 2H), 3.89 (dd, *J* = 12.7, 8.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 143.11, 136.43, 134.89, 129.64, 129.06, 128.55, 126.79, 126.77, 126.46, 124.19, 72.22, 68.56, 44.51. HRMS (APCI) calcd for C₁₅H₁₅O (M+H⁺): 211.1117; found: 211.1119. The isolated product matched spectra previously reported in the literature. (*Ref. Angew. Chem., Int. Ed.*, 2018, **57**, 319 – 323).




2-(p-tolyl)cyclohexan-1-ol

Prepared according to the general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.01 (m, 4H), 3.92 – 3.39 (m, 1H), 2.44 – 2.35 (m, 1H), 2.33 (s, 3H), 2.14 – 2.07 (m, 1H), 1.89 – 1.80 (m, 2H), 1.78 – 1.72 (m, 1H), 1.56 – 1.25 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 140.14, 136.39, 129.49, 127.77, 74.49, 52.80, 34.41, 33.39, 26.11, 25.09, 21.03. HRMS (APCI) calcd for C₁₃H₁₈NaO (M+Na⁺): 213.1250; found: 213.1253.




2-(3,4-dimethylphenyl)-2-phenylethan-1-ol

Prepared according to the general procedure, as a pale-yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.15 (m, 5H), 7.08 (d, *J* = 7.7 Hz, 1H), 7.05 – 6.95 (m, 2H), 4.22 – 4.03 (m, 3H), 2.23 (s, 3H), 2.22 (s, 3H), 1.51 (br s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 141.71, 138.72, 136.97, 135.17, 130.01, 129.69, 128.72, 128.25, 126.73, 125.55, 66.22, 53.33, 19.93, 19.39. HRMS (APCI) calcd for C₁₆H₁₈NaO (M+Na⁺): 249.1250; found: 249.1256.




2-(3,4,5-trifluorophenyl)cyclohexan-1-ol

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.01 – 6.72 (m, 2H), 3.57 (td, J = 10.0, 4.3 Hz, 1H), 2.54 – 2.30 (m, 1H), 2.19 – 2.02 (m, 1H), 2.00 – 1.65 (m, 3H), 1.55 – 1.19 (m, 5H). ^{19}F NMR (376 MHz, CDCl_3) δ -134.46, -134.51, -163.32, -163.37, -163.43. ^{13}C NMR (101 MHz, CDCl_3) δ 151.23 (ddd, J = 249.7, 9.8, 4.1 Hz), 140.14 (td, J = 6.6, 4.6 Hz), 138.40 (dt, J = 249.8, 15.3 Hz), 111.67 (dd, J = 15.4, 5.5 Hz), 74.12, 52.42, 34.98, 33.24, 25.70, 24.86. HRMS (APCI) calcd for $\text{C}_{12}\text{H}_{13}\text{F}_3\text{NaO}$ ($\text{M}+\text{Na}^+$): 253.0811; found: 253.0815.




1-(4-(2-hydroxycyclohexyl)phenyl)ethan-1-one

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.02 – 7.77 (m, 2H), 7.66 – 7.30 (m, 2H), 3.83 – 3.66 (m, 1H), 2.63 – 2.44 (m, 4H), 2.26 – 2.09 (m, 1H), 1.96 – 1.74 (m, 3H), 1.57 – 1.29 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 197.79, 149.50, 135.74, 128.78, 128.09, 74.11, 53.17, 34.87, 33.22, 26.56, 25.86, 24.99. HRMS (APCI) calcd for $\text{C}_{14}\text{H}_{18}\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 241.1199; found: 241.1197.




2-(4-(hydroxymethyl)phenyl)-2-phenylethan-1-ol


Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.36 – 7.16 (m, 9H), 4.64 (s, 2H), 4.27 – 4.11 (m, 3H), 1.77 (br s, 1H), 1.63 (br s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 141.30, 140.93, 139.41, 128.76, 128.53, 128.27, 127.46, 126.88, 66.09, 65.05, 53.35. HRMS (APCI) calcd for $\text{C}_{15}\text{H}_{16}\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 251.1043; found: 251.1046.

**4-(2-hydroxycyclohexyl)benzaldehyde**

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 9.98 (s, 1H), 7.85 (d, $J = 8.3$ Hz, 2H), 7.43 (d, $J = 8.3$ Hz, 2H), 3.83 – 3.60 (m, 1H), 2.64 – 2.42 (m, 1H), 2.29 – 2.04 (m, 1H), 1.94 – 1.75 (m, 3H), 1.63 – 1.27 (m, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 191.93, 151.12, 135.20, 130.19, 128.57, 74.14, 53.37, 34.93, 33.22, 25.82, 24.97. HRMS (APCI) calcd for $\text{C}_{13}\text{H}_{16}\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 227.1043; found: 227.1041.



**2-(benzofuran-2-yl)cyclohexan-1-ol**

Prepared according to the general procedure, as a pale-yellow liquid. ^1H NMR (400 MHz, CDCl_3) δ 7.54 – 7.48 (m, 1H), 7.43 (ddd, $J = 3.2, 1.9, 0.9$ Hz, 1H), 7.26 – 7.13 (m, 2H), 6.51 (d, $J = 0.6$ Hz, 1H), 3.87 – 3.48 (m, 1H), 2.77 – 2.58 (m, 1H), 2.13 (ddd, $J = 7.6, 4.7, 1.5$ Hz, 1H), 2.03 (ddd, $J = 13.2, 6.0, 2.8$ Hz, 1H), 1.89 – 1.77 (m, 2H), 1.74 – 1.59 (m, 1H), 1.47 – 1.27 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.27, 154.68, 128.51, 123.57, 122.68, 120.54, 111.00, 102.71, 72.68, 46.36, 34.29, 30.10, 25.36, 24.60. HRMS (APCI) calcd for $\text{C}_{14}\text{H}_{16}\text{NaO}_2$ ($\text{M}+\text{Na}^+$): 239.1043; found: 239.1046.


**(S)-1-([1,1'-biphenyl]-4-yl)butan-2-ol**

Prepared according to the general procedure, as a pale-yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.56 (dd, $J = 15.1, 7.8$ Hz, 4H), 7.43 (t, $J = 7.5$ Hz, 2H), 7.31 (dd, $J = 19.9, 7.5$ Hz, 3H), 4.01 – 3.55 (m, 1H), 2.87 (dd, $J = 13.6, 3.9$ Hz, 1H), 2.69 (dd, $J = 13.5, 8.4$ Hz, 1H), 1.66 – 1.34 (m, 3H), 1.01 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 140.95, 139.41, 137.80, 129.89, 128.80, 127.30, 127.19, 127.05, 74.08, 43.22, 29.71, 10.13. HRMS (APCI) calcd for $\text{C}_{16}\text{H}_{18}\text{NaO}$ ($\text{M}+\text{Na}^+$): 249.1250; found: 249.1252.

Scheme S1. Experiment of chiral epoxide



Chiralpak AD-H column, $\lambda = 214 \text{ nm}$, n-hexane/i-PrOH (90:10)

Peak[#]	RetTime[min]	Height[uV]	Width[min]	Area[uV*s]	Area[%]
1	6.359	1886000	0.129	15486987	49.433
2	6.830	1809488	0.137	15842481	50.567



Peak[#]	RetTime[min]	Height[uV]	Width[min]	Area[uV*s]	Area[%]
1	6.355	2851615	0.141	25413108	99.448
2	6.828	17484	0.122	141007	0.552



Scheme S2. Mechanism experiment of chiral epoxide

Chiralpak OJ-H column, $\lambda = 214 \text{ nm}$ 


<峰表>

峰号	保留时间	面积	高度	浓度	浓度单位	标记	化合物名
1	21.608	20701170	645992	49.805			
2	23.853	20863295	566018	50.195		V	
总计		41564465	1212010				


Scheme S3. Hammett analysis of the reaction




Scheme S4. X-ray diffraction analysis




CCDC Deposition Number: 1967481




5. NMR Spectra





Supporting Information





Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information





Supporting Information





Supporting Information





Supporting Information





Supporting Information




Supporting Information





Supporting Information





Supporting Information





Supporting Information




Supporting Information





Supporting Information




Supporting Information





Supporting Information




Supporting Information





Supporting Information





Supporting Information




Supporting Information




Supporting Information





Supporting Information





Supporting Information




Supporting Information




Supporting Information





Supporting Information




Supporting Information





Supporting Information




Supporting Information





Supporting Information





Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information




Supporting Information





Supporting Information





Supporting Information




Supporting Information





Supporting Information





Supporting Information



Supporting Information



Supporting Information



Supporting Information

